• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Atlas Engineered Prods
Blue Gold Limited - Warrant
Cumulus Media Inc
Defiance China Memory ETF
IDEX Corporation Common Stock
Integral Ad Science Holding Corp. - Common Stock
Jabil Inc. Common Stock
Microbix Biosystems Inc
Mitsubishi Shokuhin Co. Ltd
VanEck Agribusiness ETF
VanEck Fabless Semiconductor ETF
Vornado Realty Trust
Edit Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
Standard & Poors 500
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Odyssey Therapeutics, Inc. - Common Stock (NQ:ODTX)

19.60 +0.52 (+2.73%)
Delayed Quote Updated: 4:00 PM EDT, Oct 23, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 209,595
Open 19.02
Bid (Size) 18.40 (100)
Ask (Size) 20.40 (100)
Prev. Close 19.08
Today's Range 18.37 - 20.07
52wk Range 15.10 - 29.05
Shares Outstanding N/A
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Odyssey Therapeutics Highlights OD-001 Phase IIa UC Data, Sets 2027 Trial Readouts ↗
Today 12:02 EDT
Odyssey Therapeutics (NASDAQ:ODTX) presented additional data from its open-label Phase IIa trial of OD-001, an oral RIPK2 scaffolding inhibitor for moderate-to-severe ulcerative colitis, during its UEG... 
Via MarketBeat
News headline image
Odyssey Therapeutics Presents Completed Phase 2a OD-001 Induction Results Strengthening Clinical Proof of Concept at UEG Week 2026
October 20, 2026
From Odyssey Therapeutics Inc
Via GlobeNewswire

Performance

52-Week Range 32.5% below 52-week high
19.60
15.1052W Low 29.0552W High
1 Week 2.3% below 1-week high
16.931W Low 20.071W High

Odyssey Therapeutics, Inc. - Common Stock (ODTX) traded between $15.10 and $29.05 over the past 52 weeks and last traded at $19.60, 32.5% below its 52-week high. Over the past week it ranged between $16.93 and $20.07.

Past 12 Months
+8.3%
-1.7%
+3.0%
+19.4%
+19.4%
+19.4%
1W +$1.50
1M -$0.33
3M +$0.57
6M +$3.18
YTD +$3.18
1Y +$3.18

ODTX was +19.4% over the past year, +19.4% over six months, +19.4% year to date, +8.3% in the last week.

12 Months vs Market
ODTX
+19.4%
DIA
+10.4%
SPY
+12.2%
QQQ
+14.1%
IWM
+10.6%

Over the past 12 months ODTX returned +19.4% versus DIA (Dow) +10.4%, SPY (S&P 500) +12.2%, QQQ (Nasdaq 100) +14.1% and IWM (Russell 2000) +10.6%.

Volume & Liquidity 0.81× 3-mo avg
Today 209,595 3-mo avg 259.0K
1W
244.9K
1M
263.2K
3M
259.0K
6M
323.2K
YTD
323.2K
1Y
323.2K

ODTX most recently traded 209,595 shares against a 3-month average daily volume of 259.0K.

More News

Read More
News headline image
Odyssey Therapeutics to Present Design of Phase 2a Study Evaluating OD-001 in Combination with Vedolizumab at ACG 2026
October 12, 2026
From Odyssey Therapeutics Inc
Via GlobeNewswire
News headline image
Odyssey Therapeutics Announces Oral Presentation of Additional Phase 2a Induction Data for OD-001 in Ulcerative Colitis at UEG Week 2026
October 06, 2026
From Odyssey Therapeutics Inc
Via GlobeNewswire
News headline image
Odyssey Therapeutics to Participate in Stifel 2026 Virtual Immunology and Inflammation Forum
September 16, 2026
From Odyssey Therapeutics Inc
Via GlobeNewswire
News headline image
Odyssey Therapeutics to Participate in Upcoming Investor Conferences
August 26, 2026
From Odyssey Therapeutics Inc
Via GlobeNewswire
News headline image
Odyssey Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
August 04, 2026
From Odyssey Therapeutics Inc
Via GlobeNewswire
News headline image
Odyssey Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
June 17, 2026
From Odyssey Therapeutics Inc
Via GlobeNewswire

Frequently Asked Questions

Is Odyssey Therapeutics, Inc. - Common Stock publicly traded?
Yes, Odyssey Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Odyssey Therapeutics, Inc. - Common Stock trade on?
Odyssey Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Odyssey Therapeutics, Inc. - Common Stock?
The ticker symbol for Odyssey Therapeutics, Inc. - Common Stock is ODTX on the Nasdaq Stock Market
What is the current price of Odyssey Therapeutics, Inc. - Common Stock?
The current price of Odyssey Therapeutics, Inc. - Common Stock is 19.60
When was Odyssey Therapeutics, Inc. - Common Stock last traded?
The last trade of Odyssey Therapeutics, Inc. - Common Stock was at 10/23/26 04:00 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap